Trial Profile
A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients With Brain Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Pritumumab (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Brain cancer; Brain metastases; Chordoma; Craniopharyngioma; Glioblastoma; Glioma; Medulloblastoma; Meningioma; Non-small cell lung cancer; Oligodendroglioma; Pituitary cancer
- Focus Adverse reactions
- Acronyms NAS-101
- Sponsors Nascent Biotech
- 07 Jun 2023 According to a Nascent Biotech Media Release, results from this study were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
- 06 Jun 2023 Results (n=15) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 09 May 2023 According to Nascent Biotech media release, Company will have a clinical trials medical team member presenting the pivotal results from the NAS-101 trial at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting